Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Enspryng (satralizumab-mwge) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Satralizumab demonstrated a significantly lower risk of relapse compared to standard treatments, with a hazard ratio (HR) of 0.13 (95% CI: 0.07, 0.24), and it reduced the annualized relapse rate (ARR) by a mean difference of -0.27 (-0.37, -0.16).
• In terms of the Expanded Disability Status Score (EDSS), satralizumab showed subtle improvements, and in two trials, a reduction in EDSS from baseline was observed, although it was not significantly superior to other treatments.
• In the SAkura studies, 70% to 80% of patients treated with satralizumab remained relapse-free, highlighting its effectiveness in maintaining relapse-free status among patients with NMOSD.
• New molecules, including satralizumab, demonstrated a favorable safety profile with fewer adverse events compared to older treatments like azathioprine, although specific adverse event rates for satralizumab were not detailed.
• Satralizumab's safety findings were noted to be similar to tocilizumab, with an acceptable toxicity profile; however, specific rates for adverse and serious adverse events were not isolated for satralizumab.
• There is no population type or subgroup information available in the reviewed studies.